Sevibe Cells – the only bank in Spain accredited with AABB

In October 2015 Sevibe Cells became the first bank in Spain accredited by the American Association of Blood Banks (AABB) – internationally recognized symbol of quality of products and services in the filed of cord blood banking. Being accredited by AABB means that all Clients of Sevibe Cells can be sure that we meet the highest standards in several different fields from quality management system essentials to technical requirements. In order to achieve this accreditations any cord blood bank has to present the highest level of safety of collecting, processing, testing, distributing and administering of the precious product.

There are 117 cord blood banks in Europe, only 5 ( 3 of them belong to Famicord Group) received this prestigious accreditation. “It’s a very demanding accreditation,” says Eloi Palà, General Manager of Sevibe Cells, which also requires a permanent effort to continuously improve and control processes to ensure greater safety in a case of eventual transplant. The American Associaton of Blood Banks carries out periodic audits to verify the implementation of the quality systems implemented, guaranteeing the safety of the samples to be released in case of clinical use. In addition, all accredited banks must take on a continuous improvement plan, obligatory to renew accreditation”.

Recently added

17 November 2025 FamiCord Group Recognized as Europe’s Leading Stem Cell Bank FamiCord is the largest stem cell bank in Europe and the third largest in the world. The quality of its services is validated by international certifications, and the company has now been recognized as Europe’s Leading Stem Cell Bank by Life Sciences Review, highlighting its commitment to excellence, clinical reliability, and innovation in stem cell banking.FamiCord Group have been awarded as “The Europe’s Leading Stem Cell Bank” , independent experts jury underlined FamiCord has established itself as a leading provider in the field, guiding families through the collection, processing, and long-term preservation of cord blood and perinatal tissues. Read more
27 August 2025 Infantile cerebral palsy – Convincing evidence for the use of perinatal stem cells Leipzig, July 15, 2025 - Cerebral palsy (CP) continues to be one of the most common motor disabilities in childhood and is associated with permanent movement restrictions and spasticity. The therapeutic potential of stem cells from umbilical cord blood and tissue was discussed at the 37th Annual Meeting of the European Academy Of Childhood-onset Disabilities (EACD) and the 4th Meeting of the International Alliance of Academies of C hildhood Disability (IAACD) from June 24 - 28, 2025 in Heidelberg. As part of a symposium supported by FamiCord AG, international experts presented the current state of research and reported on the results from clinical practice. Read more